Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
The Therapeutic Goods Administration (TGA) has tested a product labelled Semenax capsules and found that:
- they contained the undeclared substance Yohimbine.
Consumers are advised that Yohimbine is considered to be a prescription-only substance and prohibited import into Australia.
The product tested containing Yohimbine was a counterfeit version of Semenax capsules.
The supply of Semenax capsules (counterfeit or otherwise) is illegal in Australia
Semenax capsules (counterfeit or otherwise) have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation.
Information for consumers
- Stop taking Semenax capsules (as shown in the photograph) and take any remaining capsules to your local pharmacy for safe disposal.
- If you have any concerns arising from your use of this product, consult your health care practitioner.
Action the TGA is taking
The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Semenax capsules containing Yohimibine from entering Australia.
If these capsules are found at the border by the ABF they will be seized and destroyed.
The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:
- may contain undisclosed and potentially harmful ingredients
- may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.